Proposal for ZLN005 (Sigma-Aldrich, Cat. #SML1555)

Overview of Therapeutic Candidate:
ZLN005 is a synthetically produced small molecule, classified chemically as a benzodiazepine derivative with the molecular formula C17H18N2 and a molecular weight of 250.34. It was initially discovered and characterized as a transcriptional activator of the peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha (PGC1α), a master regulator of mitochondrial biogenesis and energy metabolism (Tohme et al., 2024). As a representative of the class of small molecules designed to modulate transcriptional coactivators, ZLN005 has been engineered to enhance the expression and activity of PGC1α, thereby stimulating mitochondrial gene expression cascades including those that regulate fatty acid oxidation (Miller et al., 2019). This compound is commercially available from Sigma-Aldrich (Cat. # SML1555) and belongs to a group of investigational molecules that have been primarily explored in the context of metabolic and ischemia-reperfusion injury models. The design principles underlying its synthesis are rooted in medicinal chemistry efforts to mimic the beneficial effects of exercise on mitochondrial function by upregulating endogenous mitochondrial regulators. In general, compounds of this class have been used in preclinical settings to investigate protective effects in organ systems vulnerable to metabolic stress, and they offer potential as metabolic enhancers due to their ability to induce mitochondrial biogenesis (Tohme et al., 2024).

Therapeutic History:
ZLN005’s therapeutic history is primarily found in preclinical research where its ability to upregulate PGC1α has been exploited to improve mitochondrial function in several experimental models. For example, studies in cardiac, renal, and neural tissues have explored its protective effects against ischemia-reperfusion injury, revealing reductions in oxidative stress and apoptotic cell death together with an enhancement in mitochondrial mass (Tohme et al., 2024). In hepatic models, although data are more limited, ZLN005 has been shown to reduce liver triglycerides, diminish inflammatory markers, and enhance mitochondrial DNA content in rodent steatosis models. This aligns with a significant body of literature linking mitochondrial dysfunction to the progression of Non-alcoholic Steatohepatitis (NASH) (ClinicalTrials.gov, n.d.). Its use in in vitro models such as HepG2 cell assays has also demonstrated an increase in PGC1α mRNA and protein levels, with concomitant rises in oxygen consumption and fatty acid oxidation enzyme expression (Mello et al., 2016). While there are currently no extensive clinical studies directly testing ZLN005 in NASH patients, an extensive clinical trial database search (ClinicalTrials.gov, n.d.) suggests that molecules targeting PGC1α pathways are under active investigation, providing further impetus for repurposing ZLN005 toward the treatment of NASH (Tohme et al., 2024).

Mechanism of Action:
At the molecular level, ZLN005 acts as a transcriptional activator for PGC1α, which is central to the biogenesis and functional optimization of mitochondria. By elevating PGC1α mRNA and protein levels, it triggers a cascade of transcriptional events including the induction of nuclear respiratory factors (NRF1 and NRF2) and mitochondrial transcription factor A (TFAM) that are necessary for the replication of mitochondrial DNA and the assembly of oxidative phosphorylation complexes (Tohme et al., 2024; Miller et al., 2019). Several studies have demonstrated that ZLN005 increases the mitochondrial DNA content and elevates oxygen consumption rates in cell models, supporting the notion that its action is mediated through enhanced mitochondrial oxidative capacity (Mello et al., 2016). Furthermore, mechanistic validation through chromatin immunoprecipitation (ChIP) experiments has revealed increased binding of activated PGC1α to the promoters of genes encoding enzymes involved in β-oxidation. This directly implicates ZLN005 in the upregulation of fatty acid oxidation pathways—a critical aspect of improving metabolic dysfunction in hepatocytes with lipid overload (Tohme et al., 2024). Indirect activation via upstream kinases such as AMPK has been noted, although some time-dependent studies indicate that changes in phospho-AMPK levels may not be markedly significant at early time points, with the downstream TFAM promoter activity serving as a more sensitive readout of the drug’s effect (Moradi, 2022). In summary, the biochemical action of ZLN005 involves modulation of transcriptional networks governing mitochondrial biogenesis and fatty acid catabolism, processes that are fundamentally impaired in NASH (Miller et al., 2019).

Expected Effect:
Given the central role of mitochondrial dysfunction and impaired fatty acid oxidation in the pathogenesis of NASH, the hypothesis that ZLN005 will enhance mitochondrial biogenesis and upregulate β-oxidation enzyme expression in hepatocytes is strongly supported by the preclinical literature. By increasing the transcriptional output of PGC1α, ZLN005 is expected to enhance the expression of key enzymes involved in fatty acid β-oxidation, such as medium-chain acyl-CoA dehydrogenase (MCAD) and long-chain acyl-CoA dehydrogenase (LCAD), and promote the overall mitochondrial oxidative capacity (Tohme et al., 2024). Improved mitochondrial biogenesis leads to an increased number of functional mitochondria, thereby elevating the cellular capacity to oxidize fatty acids. In turn, this will reduce hepatocellular lipid accumulation—a hallmark of NASH—and decrease the generation of lipotoxic intermediates that drive inflammatory signaling and fibrosis. Preclinical rodent studies have already demonstrated that treatment with ZLN005 correlates with decreased liver triglyceride levels and reduced markers of inflammation, suggesting that this compound effectively reverses lipid overload and its deleterious downstream effects on hepatic metabolism (Tohme et al., 2024; Mello et al., 2016). Moreover, the proposed mechanism is further validated by findings that indicate increased oxygen consumption and mitochondrial DNA content upon treatment in hepatocyte cell lines, thereby creating a strong rationale for improved fatty acid catabolism in NASH hepatocytes. The positive modulation of mitochondrial biogenesis and cellular energy metabolism by ZLN005 also aligns with data obtained from exercise-induced adaptations in the liver, a known protective mechanism against NASH (Tohme et al., 2024).

Overall Evaluation:
ZLN005 presents as a promising therapeutic candidate for NASH based on its well-characterized mechanism of action and the strong preclinical evidence supporting its ability to enhance mitochondrial biogenesis and fatty acid oxidation. One of the primary strengths of this candidate is its clear mechanistic linkage via the activation of PGC1α, which is a critical node in mitochondrial and metabolic regulation. This compound not only induces PGC1α expression but also promotes the downstream transcription of mitochondrial genes and β-oxidation enzymes as supported by studies in both cell-based assays and rodent models (Mello et al., 2016; Tohme et al., 2024). Given that mitochondrial dysfunction is a central pathogenic factor in NASH, the ability of ZLN005 to potentially restore mitochondrial homeostasis is a significant asset. The molecule’s oral bioavailability further adds to its appeal as a drug candidate since this mode of delivery is advantageous in chronic diseases such as NASH.

However, there are also weaknesses that must be taken into account. First, while the preclinical data are compelling in models of steatosis and ischemia-reperfusion injury, there is currently a paucity of studies directly investigating the effects of ZLN005 in established NASH models. As a result, the translation of improvements in mitochondrial biogenesis to meaningful clinical outcomes in NASH patients remains to be confirmed. Second, the time-dependent effects on key upstream mediators like AMPK have shown some variability, suggesting that the timing and dosage of administration must be optimized to achieve the desired mitochondrial and metabolic responses (Moradi, 2022). Third, potential off-target effects and the long-term safety profile of ZLN005 in chronic administration have not yet been fully explored in vivo. Although the compound has demonstrated hepatoprotective effects in rodent models, comprehensive toxicology studies and phase I clinical trials would be necessary to firmly establish its safety profile prior to broader clinical testing in NASH.

Another consideration is the relative novelty of the compound’s application for NASH despite the well-established role of PGC1α in hepatic metabolism. While the rationale is robust, the lack of extensive human data specifically linking ZLN005 treatment to NASH improvement means that further preclinical validation in hepatic models, including studies using primary human hepatocytes and NASH-specific animal models, is required before definitive conclusions can be reached. In addition, the complexity of NASH pathogenesis—encompassing not just lipid metabolism but also inflammation, fibrosis, and insulin resistance—might necessitate combination therapies. ZLN005’s use as a monotherapy might therefore need to be carefully integrated into a broader treatment regimen or combined with other agents targeting complementary pathways.

In summary, the overall evaluation favors further development of ZLN005 as a potential repurposed drug candidate for NASH treatment. Its strengths include a compelling mechanism of action via PGC1α activation leading to enhanced mitochondrial biogenesis, increased β-oxidation enzyme expression, and consequent improvements in fatty acid catabolism and reduced lipid deposition—mechanistic outcomes that are highly relevant to the pathogenesis of NASH (Mello et al., 2016; Miller et al., 2019; Tohme et al., 2024). The challenges lie in addressing the current gaps in direct NASH-specific in vivo data, optimizing dosing strategies, and confirming long-term safety and efficacy. Given the current landscape of metabolic therapeutics and the ongoing clinical interest in targeting mitochondrial dysfunction in NASH (ClinicalTrials.gov, n.d.), advancing ZLN005 into more rigorous preclinical studies is warranted, with an eventual aim to integrate it into clinical trials if the data continue to support its therapeutic potential.

Overall, ZLN005’s use as a repurposed therapeutic candidate for NASH is scientifically rational and supported by relevant preclinical data. However, the drug development team should prioritize generating additional mechanistic and in vivo efficacy data specifically in NASH models, while concurrently investigating the detailed pharmacokinetics and safety profile in long-term animal studies. These steps will substantiate whether the beneficial mitochondrial effects observed in other organs and in vitro systems can be extended to the complex pathophysiology of NASH, ultimately guiding the design of future clinical trials (Mello et al., 2016; Miller et al., 2019; Moradi, 2022; Tohme et al., 2024).

References
ClinicalTrials.gov. (n.d.). ClinicalTrials.gov search: ZLN005 OR PGC1α activator AND NASH OR Non-alcoholic Steatohepatitis. Retrieved June 1, 2024, from https://clinicaltrials.gov/

Mello, T., Materozzi, M., & Galli, A. (2016). PPARs and mitochondrial metabolism: From NAFLD to HCC. PPAR Research. https://doi.org/10.1155/2016/7403230

Miller, K. N., Clark, J. P., & Anderson, R. M. (2019). Mitochondrial regulator PGC-1α: Modulating the modulator. Current Opinion in Endocrine and Metabolic Research, 5, 37–44. https://doi.org/10.1016/j.coemr.2019.02.002

Moradi, N. (2022). Investigating the time-dependent effects of sulforaphane, urolithin A, and ZLN005 as inducers of mitochondrial turnover in muscle. Unknown Journal.

Tohme, C., Haykal, T., Yang, R., Austin, T. J., Loughran, P., Geller, D. A., Simmons, R. L., Tohme, S., & Yazdani, H. O. (2024). ZLN005, a PGC-1α activator, protects the liver against ischemia–reperfusion injury and the progression of hepatic metastases. Cells, 13(17), 1448. https://doi.org/10.3390/cells13171448
